PHARMACY

FDA approves two Novo Nordisk insulin pens

BY Alaric DeArment

PLAINSBORO, N.J. — The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.

Novo Nordisk announced the FDA approval of Novolog FlexTouch (insulin aspart [rDNA origin]) and Levemir FlexTouch (insulin detemir [rDNA origin]).

FlexTouch is a new profiled insulin delivery system that allows patients to administer insulin by pressing a low-dose-force button. In traditional insulin pens, a push button extends when a dose is dialed, which can present challenges for a patient at higher doses, the company said.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Dr. Reddy’s sales increase by 17%

BY Alaric DeArment

HYDERABAD, India — Indian drug maker Dr. Reddy’s Labs had sales of $536 million in second-quarter 2014 and profits of $110 million, the company said.

Those figures represented sales growth of 17% and a 76% growth in profits over second quarter 2013. Seventy-nine percent of the company’s sales came from generic drugs, including 50% from sales in North America; sales of generics grew by 32% over last year.

During the quarter, the company filed four applications for new generics with the Food and Drug Administration, and it currently has 62 applications pending, of which 39 contain challenges to branded drug patents, and nine are potential "first-to-file" drugs for which the company would get 180 days in which to compete exclusively against the branded versions of the drugs upon FDA approval.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Teva sales increase by 2%

BY Alaric DeArment

JERUSALEM — Teva Pharmaceutical Industries had $5.1 billion in sales and $711 million in profits in third-quarter 2013, the Israeli drug maker said.

Sales for the quarter represented a 2% increase in sales over third quarter 2012 and included $2.7 billion in U.S. sales, a 4% increase over one year ago; the company had a $79 million loss in third quarter 2012. In the United States, nearly $1.14 billion in sales came from generic drugs, up from $1.07 billion in second quarter 2012, while $1.5 billion came from the company’s specialty division, which includes its branded drugs business.

Copaxone (glatiramer acetate), an injected drug used to treat multiple sclerosis, had sales of $1.05 billion, a 1% increase over third quarter 2012, while the cancer drug Treanda (bendamustine) had sales of $184 million, a 15% increase over last year, and Teva Women’s Health had sales of $126 million, a 31% increase.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?